Evofem Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Product sales, net | $2,633 | $4,825 | $3,532 | $5,670 |
| Operating Expenses: | ||||
| Cost of goods sold | 511 | 755 | 921 | 1,120 |
| Amortization of intangible asset | 14 | 107 | 89 | 330 |
| Research and development, net | 694 | 746 | 1,212 | (4,289) |
| Selling and marketing | 2,075 | 2,625 | 4,168 | 5,225 |
| General and administrative | 1,828 | 1,843 | 4,200 | 4,208 |
| Total operating expenses | 5,122 | 6,076 | 10,590 | 6,594 |
| Loss from operations | (2,489) | (1,251) | (7,058) | (924) |
| Other income (expense): | ||||
| Interest income | 3 | 2 | 5 | 10 |
| Other expense, net | (613) | (662) | (1,350) | (1,262) |
| Loss on debt extinguishment | (2,192) | - | (2,192) | - |
| Change in fair value of financial instruments | (5,745) | 134 | (5,907) | 1,355 |
| Total other income (expense), net | (8,547) | (526) | (9,444) | 103 |
| Loss before income tax expense | (11,036) | (1,777) | (16,502) | (821) |
| Income tax benefit (expense) | - | (7) | 1 | (7) |
| Net loss | (11,036) | (1,784) | (16,501) | (828) |
| Convertible and redeemable preferred stock deemed dividends | (108) | (1) | (128) | (4) |
| Net loss attributable to common stockholders | $(11,144) | $(1,785) | $(16,629) | $(832) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.08) | $(0.01) | $(0.12) | $(0.01) |
| Weighted-average shares used to compute net loss per share attributable to common shareholders, basic and diluted | 137,337,773 | 120,493,716 | 135,303,619 | 119,335,317 |
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.